MedPath
HSA Approval

MOFECON-GR 360 GASTRO-RESISTANT TABLETS 360 MG

SIN16970P

MOFECON-GR 360 GASTRO-RESISTANT TABLETS 360 MG

MOFECON-GR 360 GASTRO-RESISTANT TABLETS 360 MG

March 8, 2024

GOLDPLUS UNIVERSAL PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantGOLDPLUS UNIVERSAL PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, ENTERIC COATED

ORAL

Medical Information

L04AA06

mycophenolic acid

Manufacturer Information

GOLDPLUS UNIVERSAL PTE LTD

CONCORD BIOTECH LIMITED

Active Ingredients

Mycophenolate Sodium 384.70mg eqv Mycophenolic Acid

360mg

Mycophenolic acid

Documents

Package Inserts

1.4.3 Mofecon-GR Tablet (VIMOFxx-12) SIN_Nov23.pdf

Approved: March 8, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

MOFECON-GR 360 GASTRO-RESISTANT TABLETS 360 MG - HSA Approval | MedPath